#USA #Boston #Morphic Medical #RESET #Dr. Terri Cooper

Morphic Medical Welcomes New Board Members

Morphic Medical, a pioneer in healthcare, known for its groundbreaking device aimed at tackling the underlying causes of Type 2 diabetes, has announced pivotal additions to its leadership team. The company has appointed Dr. Terri Cooper as the Chairperson of its Board of Directors and Craig Richardson as a new non-executive board member. This leadership change is set to strengthen the company's mission and enhance its growth trajectory.

Leadership Vision Ahead

With Dr. Cooper at the helm as Chairperson, Morphic Medical is gearing up for its next phase of expansion. Dr. Cooper brings extensive experience in building successful healthcare enterprises, making her an ideal leader for guiding Morphic Medical's strategic direction. Her role will involve close collaboration with the management team to ensure effective governance and long-term value creation during this exciting development phase.

In Dr. Cooper's own words, "Morphic Medical has developed promising and innovative technology that could revolutionize the management of obesity and metabolic diseases. Having reached significant clinical, regulatory, and commercial milestones, the company is well-positioned to enter this crucial growth period. I look forward to working with the board and the management team to establish our company as a global leader in metabolic health."

New Insights on Patient Access

Joining her on the board, Craig Richardson is expected to provide vital insights from his extensive background in health economics, market access, and value creation within the healthcare sector. His expertise will be critical as Morphic Medical engages with payers, providers, and policymakers to expand patient access to its innovative treatment, RESET®.

According to Richardson, "The burden of obesity and Type 2 diabetes on health systems continues to escalate globally, making it paramount that innovative treatments demonstrate both strong clinical outcomes and economic value. RESET® could offer significant benefits to patients while simultaneously reducing long-term healthcare costs. I am excited to join the board and assist Morphic Medical in gathering the scientific data and forming the partnerships necessary to optimize patient access to our therapies."

Acknowledging Previous Leadership

Mike Gutteridge, CEO of Morphic Medical, expressed gratitude towards the outgoing chairperson Mark Lerdal for his leadership and contributions to the company. As the company looks forward to Dr. Cooper's and Richardson’s leadership, Gutteridge remarked, "Terri's strategic leadership and substantial experience in creating successful healthcare businesses make her the perfect person to lead Morphic Medical into the next stage of growth. Craig’s deep expertise in health economics and reimbursement will be invaluable as we continue to demonstrate the clinical and economic value of RESET® to health systems worldwide. Together, they bring considerable reinforcement to our board and bolster our commitment to improving the lives of patients grappling with obesity and Type 2 diabetes."

Commitment to International Expertise

These appointments underline Morphic Medical's ongoing dedication to assembling a board with international caliber expertise, essential for supporting its business strategy, global expansion, and long-term mission to enhance clinical outcomes for patients suffering from obesity and Type 2 diabetes.

About Morphic Medical

Founded in 2003 and headquartered in Boston, Morphic Medical is the developer of RESET, an endoscopic treatment that serves as a non-surgical alternative for morbid obesity and related cardiometabolic risk factors, such as Type 2 diabetes. RESET is currently approved for sale in the European Union and the UK, while its use in the U.S. is limited to clinical research. For more information, please visit morphicmedical.com or follow the company on Twitter and LinkedIn.